MetCure received a $160,996 Phase I Small Business Technology Transfer (STTR) grant from the National Cancer Institute. This project is to investigate the efficacy of a novel nutraceutical agent ProFine in enhancing standard prostate cancer therapy.
MetCure received a $160,996 Phase I Small Business Technology Transfer (STTR) grant from the National Cancer Institute. This project is to investigate the efficacy of a novel nutraceutical agent ProFine in enhancing standard prostate cancer therapy.
MetCure Therapeutics LLC